GSK to buy US cancer drug firm IDRx for up to $1.15bn
by Julia Kollewe from US news | The Guardian on (#6TH9Y)
Massachusetts-based company is working on new treatments for gastrointestinal cancers
GSK has struck a deal worth up to $1.15bn (950m) to acquire a Massachusetts-based developer of rare cancer therapies, in an attempt to bolster its expanding oncology business.
GSK, Britain's second-biggest drugmaker behind AstraZeneca, said the acquisition of IDRx, based in Plymouth near Boston, would help it target a major gap in the current standard of care" related to gastrointestinal cancers.
Continue reading...